Viyash Scientific Ltd announces an acquisition

Viyash is expected to fund the acquisition predominantly from internal accruals and available liquidity, with only EUR 4–5 million of external, likely short-term, borrowing. On a full-settlement basis, the transaction would mechanically increase consolidated net debt-to-equity from 0.06x to approximately 0.13x. The more visible effect would be on cash headroom rather than leverage.

Funding mix

The later SPA summary puts the total consideration at EUR 16.976 million, comprising EUR 15.0 million payable at closing and EUR 1.976 million deferred, equivalent to approximately 88.37% upfront and 11.63% deferred ^[1].

ICRA expects the funding to comprise:

Notes: † Derived from the EUR 16.976 million SPA consideration ^[1] and ICRA’s EUR 4–5 million external-funding estimate ^[2]. The payment tranches and funding sources are separate concepts: the EUR 15 million closing payment does not mean that the entire amount will be internally funded.

Balance-sheet impact

The latest consolidated balance-sheet datapoint shows cash and equivalents of Rs 255.76 Crores, net debt of Rs 180.06 Crores, total equity of Rs 2,911.1 Crores, total debt of Rs 435.82 Crores, and a reported net debt-to-equity ratio of 0.06x ^{[3] [4] [5] [6] [7]}. The transaction has been reported at approximately Rs 188 Crores ^[8].

Notes: † Derived using the reported approximate transaction value of Rs 188 Crores ^[8]. The current-ratio calculation subtracts only the cash purchase price from current assets of Rs 2,254.6 Crores and leaves current liabilities of Rs 945.90 Crores unchanged ^{[10] [11]}; it is therefore a mechanical cash-only bridge, not the final post-acquisition consolidated balance sheet.

Under the indicated funding mix, new borrowing of EUR 4–5 million would add roughly Rs 44–55 Crores of gross debt, while the balance would be funded from cash. Net debt still rises by approximately the full Rs 188 Crores because the cash reduction and new borrowing together fund the acquisition.

Implication: the transaction is more material for liquidity than for solvency. ICRA expects overall liquidity and credit metrics to remain strong after the outflow, but the cash buffer will be materially lower, particularly if the external funding component is not drawn or if closing requires more internal cash ^[2]. The actual outcome will depend on foreign-exchange movements, net-financial-position adjustments in the SPA, the timing of the deferred payment, and the cash and debt consolidated from BioForLife ^[1].

BioForLife’s latest twelve-month revenue is approximately EUR 9.0 million, based on CY2025 sales. Its disclosed profitability is approximately a 21% operating margin; the acquisition material does not provide a separately labelled EBITDA margin, so 21% should not be treated as a confirmed EBITDA margin without that accounting definition. ^{[12] [2]}

• Revenue: approximately EUR 9.0 million for CY2025, up from EUR 8.3 million in CY2024 and EUR 7.1 million in CY2023. This is the closest disclosed proxy to TTM revenue; quarterly data for an exact rolling twelve-month calculation is not provided. ^[12]
• Margin: approximately 21% operating margin in CY2025, as reported by ICRA. A standalone EBITDA amount or explicitly defined EBITDA margin is not disclosed. ^[2]

Portfolio and strategic fit

BioForLife brings a commercial and product platform, rather than a disclosed manufacturing asset:

• Medicines and veterinary pharmaceuticals for companion animals.
• Nutraceuticals or nutritional supplements.
• Testing kits, including rapid diagnostic tests.
• Developing positions in pet dermatology and ophthalmology. ^{[8] [12]}
• An established Italian distribution network covering approximately 80% of veterinary clinics, which can support launches from Alivira’s pipeline and expansion of BioForLife products into other Alivira markets. ^[8]

Regulatory/manufacturing conclusion: the acquisition disclosure does not identify a BioForLife-specific EU-GMP certification, API/intermediate manufacturing plant, or other named manufacturing approval. BioForLife is described as being engaged almost entirely in the marketing and distribution of veterinary products in Italy, with products sourced across medicines, nutraceuticals and testing kits. ^[12] Therefore, the transaction appears to add European market access, product registrations/commercial rights and distribution reach, while Viyash’s existing manufacturing and regulatory infrastructure remains the source of the API/intermediate and broader manufacturing capability.

Separately, Viyash and its subsidiaries are described as having manufacturing operations and approvals including USFDA, EU-GMP, WHO and TGA—but that is a group-level capability, not a certification specifically attributed to BioForLife. ^[13]